Syk and tired of current chronic GVHD therapies The work of Flynn et al is also instructive because of the multiple experimental models of cGVHD that were evaluated. Although control of cGVHD cutaneous manifestations was incomplete and variable between the models, fostamatinib was relatively consistent in terms of its ability to modulate some of the immunologic end points associated with cGVHD biology. This type of diversity in modeling may help in the design of clinical trials, both with respect to types of cGVHD patients to accrue and immune end points to monitor as potential surrogates for drug activity. The inclusion of well-annotated human samples in this investigation is an advantageous feature that may assist in the more effective screening of promising agents, especially as the number of cGVHD patients and clinical trials are relatively scarce. Indeed, as exemplified in the current work, new efforts in cGVHD drug development For personal use only. on November 7, 2017. by guest www.bloodjournal.org From will benefit from an integrated multicenter cooperation between all stakeholders in the experimental modeling and clinical trial realms. 4 Clinical trials of small-molecule inhibitors of Syk that have advanced to phase 2 studies in autoimmune disease have focused on fostamatinib, which is a relatively nonspecific TKI compared with other agents that have only recently entered the drug-development pipeline; of note, fostamatinib can exacerbate hypertension, which may be due to VEGFR2 inhibition (see the recent review of Syk inhibitors by Lucas and Tan 5 ). Narrowing the specificity of Syk inhibitor therapy could ultimately improve safety, although therapeutic effects of TKI therapy are sometimes mediated through multiple targets. Syk inhibitor therapy with fostamatinib can be considered in the context of a growing list of agents known to modulate B-cell-mediated cGVHD. Most recently, the US Food and Drug Administration-approved Bruton tyrosine kinase (Btk) inhibitor ibrutinib was effective against murine cGVHD. represents a novel approach to treat cGVHD (including B-cell-driven manifestations as described by Flynn et al) while also treating the underlying malignancy (see figure) . Conflict-of-interest disclosure: The authors declare no competing financial interests. The opinions expressed herein are those of the authors and do not represent the official position of the National Institutes of Health or the United States Government. n
